Magnetic Resonance Cholangiopancreatography in Living Liver Donors and Its Relationship With Post Operative Recipient Biliary Complications
NCT07715500
Chronic Liver Disease and Cirrhosis, Donor Hepatectomy
New Delhi, India
View Trial DetailsNCT Number: NCT05763446
Liver transplantation (LT) is the treatment of choice for patients with end-stage liver disease (1). LT is often associated with severe intraoperative blood loss and the literature has had a great interest in clarifying the predictive factors for transfusion requirements during this surgery. Despite the advances in surgical techniques, graft preservation, and anesthetic management achieved over the past two decades, intraoperative bleeding and blood component consumption during LT are still issues of current interest. The requirement for blood components is highly variable between different transplant centers and ranges from none to many units of red blood cells (RBC), plasma, and platelets per patient. Bleeding associated with LT is multifactorial. Among the pre-transplantation factors, portal hypertension and coagulation defects are of great importance. The latter can develop or amplify during the anaepatic and/or neohepatic phase due to the absence of hepatic metabolic function, hyperfibrinolysis or platelet sequestration in the graft. In the literature, the higher transfusion requirement (HTR) is associated with worse postoperative outcomes, with an increase in both the length of stay in the intensive care unit (ICU) and in hospital, and mortality.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
The aim of this study is to evaluate the influence of increased transfusion requirements on the prognosis of patients undergoing LT and the risk factors for HTR. HTR is defined as the consumption of packed red blood cells (GRC) ≥ 5 units in the first 24 hours of surgery.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 90 days
90-day postoperative mortality after liver transplantation
Time frame: 48 hours
Duration of invasive mechanical ventilation
Time frame: Days until discharge from ICU, an average of 5 days
Duration of intensive care unit stay
Time frame: Days until discharge from the hospital, an average of 14 days
Hospital stay duration after liver transplant
Time frame: 90 days
90-day postoperative complications after liver transplantation
Contact information is provided by the study sponsor or research team.
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Other
Predictive Factors for Massive Transfusion During Liver Transplantation: an Observational Study
Acronym: TRADIFEG
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07715500
Chronic Liver Disease and Cirrhosis, Donor Hepatectomy
New Delhi, India
View Trial DetailsNCT06257407
Liver Transplant; Complications
Besançon, France
View Trial DetailsNCT06169592
Digestive System Diseases, Fibrosis
Tashkent, Uzbekistan
View Trial DetailsNCT07169643
Liver Transplant; Complications
Barcelona, Catalonia, Spain
View Trial Details